EUVIMEDEUVIMED entdecken
Crossref

Real-world epidemiological outcomes of biologic therapy for chronic rhinosinusitis with nasal polyps: a big data analysis

E Zloczower, G G Nyquist, A Bebin, Y Lahav, M Warman

Rhinology Journal · 2025

DOI: 10.4193/rhin25.393 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rhinology Journal, 2025. Verfasst von E Zloczower und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Head and Neck Surgery, Kaplan Medical Center, Rehovot, Israel;Faculty of Medicine, Hebrew University of Jerusalem, Isra…. Hauptthemen laut MEDLINE: Sinusitis, Nasal Polyps, Rhinitis, Antibodies, Monoclonal, Humanized.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biologic therapy has emerged as a key treatment for chronic rhinosinusitis with nasal polyps (CRSwNP), particularly in refractory cases, but its effect on healthcare utilization is not well established. Methodology: We conducted a retrospective big-data analysis using the Clalit Health Services database, identifying all CRSwNP patients treated with dupilumab or mepolizumab following endoscopic sinus surgery (ESS) between 2010–2024. We assessed antibiotic and systemic steroid use, visits to clinics, emergency rooms (ER), hospitalizations, and repeat ESS before and after biologic initiation.

Results

Among 861 patients (54.2% on dupilumab, 45.8% on mepolizumab), 62% had asthma. Median therapy duration was 25 months. Mean follow-up was 130 ± 78 months before treatment and 43 ± 42 months after. Biologics significantly reduced antibiotic and systemic steroid use, as well as community clinic, hospitalization, and revision ESS rates. Serum eosinophils declined from 520 ± 440 to 430 ± 460 cells/μL.

Conclusions

Post-ESS biologic therapy in CRSwNP patients is associated with reduced healthcare utilization and systemic medication use, highlighting its positive impact on disease burden and healthcare efficiency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SinusitisNasal PolypsRhinitisAntibodies, Monoclonal, HumanizedBiological TherapyHumansRetrospective StudiesChronic DiseaseFemaleMaleMiddle AgedAdultBig DataEndoscopyAnti-Bacterial AgentsAgedTreatment OutcomeRhinosinusitis

Substanzen

Antibodies, Monoclonal, HumanizedmepolizumabdupilumabAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Otolaryngology, Head and Neck Surgery, Kaplan Medical Center, Rehovot, Israel;Faculty of Medicine, Hebrew University of Jerusalem, Israel.
  • Department of Otolaryngology and Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, United States.
  • Department of Otolaryngology, Head and Neck Surgery, Kaplan Medical Center, Rehovot, Israel.

Zitieren

APA

Zloczower, E., Nyquist, G. G., Bebin, A., Lahav, Y., & Warman, M. (2025). Real-world epidemiological outcomes of biologic therapy for chronic rhinosinusitis with nasal polyps: a big data analysis. Rhinology Journal. https://doi.org/10.4193/rhin25.393

Vancouver

Zloczower E, Nyquist GG, Bebin A, Lahav Y, Warman M. Real-world epidemiological outcomes of biologic therapy for chronic rhinosinusitis with nasal polyps: a big data analysis. Rhinology Journal. 2025. doi:10.4193/rhin25.393

BibTeX
@article{Zloczower2025,
  author = {Zloczower, E and Nyquist, G G and Bebin, A and Lahav, Y and Warman, M},
  title = {Real-world epidemiological outcomes of biologic therapy for chronic rhinosinusitis with nasal polyps: a big data analysis},
  journal = {Rhinology Journal},
  year = {2025},
  doi = {10.4193/rhin25.393}
}
Kostenlos starten →